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Introduction
Around 50% of patients admitted with acute heart failure (AHF) will die within 5 years from diagnosis. [1, 2] Thus, there is a need to identify with more precision those clinical phenotypes at higher risk of adverse outcome. [3, 4] Chronic kidney disease (CKD) is one of the most potent contributing factors aggravating prognosis of patients with AHF. [5] CKD is common, and it might affect more than 50% of hospitalized patients with AHF, 10-15% of whom will have advanced stages of renal dysfunction. [6, 7] Many studies showed that WRF during HF admission usually complicates a poorer cardiac, or renal, function and has a prognostic impact similar to that of CKD [8] [9] [10] . However, other studies did not confirm this association between WRF and prognosis: a transient WRF might be the results of aggressive decongestion and temporary kidney overload. [11] [12] [13] [14] Blood nitrogen urea (BUN) is not only a marker of renal function, but it also reflects neurohormonal activation, that enhances reabsorption of urea in the terminal inner medullary collecting duct. [15] Thus, changes in BUN in the context of minor fluctuation or renal function can be valuable to understand when a relative intravascular volume reduction is taking place in a patient with congestive status. [16] With the present study, we evaluate the prognostic relevance of worsening renal function and BUN changes in patients admitted with AHF.
Methods

Study Design
This is a retrospective, post-hoc analysis of a prospective single-centre study including 247 patients admitted with AHF who were screened for the Diur-HF Trial (clinicaltrials.gov: NCT01441245) between September 2013 and July 2015. 
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Clinical assessment and evaluation of congestion
Two physicians assessed patients at admission and graded congestion by giving one point for the presence of each of the following clinical signs, regardless of their severity: pulmonary crepitations, third heart sound, jugular venous distention, peripheral oedema and hepatomegaly, for a total of maximum 5 points. [18] . Effective decongestion was defined as complete resolution of two, or more, clinical signs of HF, or absence of clinical signs of congestion at discharge. 
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Follow-up
Patients were followed for 180 days after discharge with clinical visits and telephone contacts. The primary outcome of interest was a composite of all-cause mortality (ACM) or HF hospitalization (HFH).
Statistical analysis
Categorical data are presented as number and percentages; normally distributed continuous data as mean + SD and non-normally distributed continuous variables as median and interquartile range.
Patients with AHF were grouped by phenotypes according to WRF, BUN increase > or < 20% or by effective, or not, decongestion during hospitalisation. One-way ANOVA and Kruskal-Wallis tests were used to compare continuous variables between groups depending on the normality of the distribution, and the chi-squared test was used for categorical variables.
Different multivariable Cox proportional hazard regression models were used to investigate the relationship between WRF, BUN and outcome. Multivariable models were adjusted for clinical
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variables of interest (age, gender, hypertension, diabetes, dyslipidemia, coronary artery disease, CKD and smoking habits) chosen prospectively a priori. Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. All analyses were performed using SPSS 20.0 for Windows (SPSS Inc, Chicago IL). A 2-sided P value < 0.05 was considered statistically significant.
Results
Patient characteristics
Of the 267 patients with AHF enrolled, 12 were excluded because of end-stage renal failure and 8
were lost to follow-up, leaving a final cohort of 247 patients. 
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Discussion
Our study, conducted in a daily life clinical scenario, shows that WRF is common in patients treated for AHF, but an increase in BUN>20% from baseline is even more common. Importantly, we found that an increase in BUN>20% during admission is a powerful predictor of adverse outcome; WRF has a significant prognostic impact only if associated with an increase in BUN or with the inability to control clinical congestion. Interestingly, our results suggest that caution is needed when relief from congestion causes a disproportionate increase in BUN.
The bidirectional relation existing between heart and kidneys is well known, however the prevalence, and incidence, of renal dysfunction in patients with chronic and AHF is poorly reported in clinical trials and observational studies. Studies rarely provide a definition of renal dysfunction, and different specific phenotype of renal dysfunction might be contemplated, with different impact on clinical outcomes [23] . Importantly, no universal agreement exists to what blood marker has to be used to define, and monitor, renal function. Our findings demonstrated that patients experiencing BUN increase have also an higher prevalence of unfavorable condition such as CAD, atrial fibrillation and advanced CKD stage that could potentially impair outcome, although multivariable analysis showed that BUN is independently related to adverse event.
Otherwise, some might argue that BUN is not a specific renal marker, as it might reflect an increased neurohormonal activity and the effects of vasopressin (AVP) enhancing reabsorption of urea at the distal tubule. [16] Acute arterial underfilling and overdiuresis, occurring during aggressive treatment with diuretics, could further activate the sympathetic and AVP systems, and subsequently increase BUN levels. Importantly, circulating BUN is also elevated secondary to an increased protein catabolism, as it might happen during cachexia, which could further contribute to an adverse outcome.
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Our results appears confirmatory of previous multicenter trials conducted in the acute and chronic heart failure setting: in the OPTIME trial, a significant increase (>25%) in BUN was frequent (40%) during hospitalisations for HF, and was strongly related to increased mortality. [24] Similarly, in the ACTIV in CHF trial, BUN, but not creatinine, was an independent predictor of morbidity and mortality. [25] Moreover, the RELAX trial suggested that WRF was not a powerful predictor of poor outcome. [26] In line with the current study, that a was associated with a significantly higher risk of all-cause mortality only if there was a concomitant elevation in BUN (>25 mg/dl) [27] . Elevated levels of BUN are also powerful predictors of adverse outcome in ambulatory patients with heart failure. [28] .
Worsening congestion is one of the key reasons for admission for patients with heart failure, and the failure of its treatment it is one of the main drivers of outcome. Metra et al. showed that WRF during AHF hospitalisations is associated with increased morbidity and mortality only when clinical congestion persists at discharge, suggesting that effective decongestion might be more important than changes in renal function. [29] We expanded this data, and we identified a population of patients with AHF in whom the risk of adverse outcome remains high even when clinical congestion is effectively relieved but at the expenses of a substantial rise in BUN levels. A proof of these concepts, appears to be confirmed by two recent post hoc analysis from PROTECT and RELAX-AHF trials examining diuretic response during hospitalization phase. [26, 30, 31] Both studies showed a strict relation among poor diuretic response, renal dysfunction and congestion. In the RELAX-AHF trial, WRF was not a predictor of poor outcome, conversely BUN increase was strictly related to reduced diuretic response confirming the hypothesis that the primarily driver of Cardio-Renal Syndrome indwells at tubular level. [26] Higher levels of BUN were also one of the strongest predictors of reduced diuretic response in the PROTECT trial, supporting the concept that sustained activation of the neuro-hormonal system might increase urea reabsorption in the kidneys,
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which might precede a detectable deterioration in renal function due to hypoperfusion. [31] .
Finally, creatinine and eGFR are the two biomarkers currently involved in WRF diagnosing, unfortunately both parameters are not useful to precociously recognize WRF. In addition, they are not able to identify the causes of the underlying sudden renal deterioration (i.e tubular, glomerular, or collector duct). [23] Most of patients with reduced natriuretic and diuretic response experienced some degree of tubular damage and renal sodium avidity. Interestingly, patients with CKD displayed a better diuretic response compared to patients with preserved renal function. [32, 33] This peculiar finding confirms that previously described by Testani and colleagues in a population of stable patients with heart failure and reduced LVEF. [34] They found that use of high doses of loop diuretics is only associated with mortality in patients with elevated BUN (>21.0 mg/dl), which might reflect a significant activation of the neuro-endocrine system.
In patients with acute heart failure, cardio-renal dysfunction and neuro-hormonal activation are relevant features together with systemic congestion. Although loop diuretic are the main drug to reduce congestion, they could potentially contribute to activate neuro-hormonal with both increase in sodium concentration in the macula densa and afferent arterial vasoconstriction. An optional strategy balancing volume status with modulation of sympathetic and RAA tone could lead to a better diuretic dose optimization. [35] Limitations This is a relatively small, single center, retrospective, observational study, with limited power. It was conducted in a tertiary hospital where patients admitted with AHF are usually older and with
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more comorbidities than those enrolled in clinical trials and recent registries, which might explain the high morbidity and mortality during follow-up. [36] Also, only consenting patients considered suitable for the Diur-HF trial were screened and enrolled in this study, which introduces further selection bias. In addition, treating physicians were not blinded to clinical congestion, renal function or BUN modifications occurred during hospitalization and different therapeutic choices might have influenced results.
Clinical assessment of congestion is highly subjective and it is frequent to observe disagreement amongst colleagues assessing congestion, particularly when this is not obvious; importantly, a comprehensive clinical evaluation might also take time and all these factors might have influenced how congestion was clinically assessed.
Moreover, there is no specific algorithm to assess or grade congestion, and there is no guidance for an objective use of loop diuretics. The use of ultrasound, for instance by measuring the inferior vena cava or jugular vein diameters, or other non-invasive technologies such as spectroscopy or bioimpedance, could provide more robust methods to quantify congestion and its responses to administration of diuretics. [37, 38] Importantly, we did not serially assess weight changes and we did not measure invasively central venous pressure, right atrial pressure and left ventricle filling pressure, all of which would have provided further insight on the complex interactions between WRF, BUN and congestion.
For all these reasons, our findings should be interpreted with caution and need to be confirmed in larger, less selective, prospective cohorts.
Conclusions
Blood urea nitrogen (BUN) increase>20% during hospitalization for AHF predicts a higher rate of adverse events after discharge, regardless of changes in renal function or clinical congestion.
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Conversely, isolated WRF did not demonstrate any association with adverse outcome. If our findings will be confirmed in larger sample size, the role of WRF during hospitalization should be reviewed taking into the account BUN variability. Whether combining measurements of BUN levels with other ultrasound and biochemical methods quantifying congestion might be useful to improve outcomes, requires further investigations.
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TABLES AND FIGURES LEGEND A C C E P T E D M A N U S C R I P T simultaneously entered in the model, in the second (right column) we entered in the model the four patients' phenotypes (according to BUN increase (> or < 20%) and WRF). 1 Models were adjusted for clinical variables of interest chosen prospectively (age, gender, and hypertension, diabetes, dyslipidemia, CHD, CKD and smoking habits). 
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REHOSPITALIZATION or DEATH
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Highlights  The prognostic relevance of kidney function in acute heart failure has been investigated with contradictory results.
 The definition of worsening renal function may be challenged with introduction of blood urea nitrogen evaluation.
 Worsening renal function evaluation for blood urea nitrogen values could improve acute cardio-renal syndrome diagnosis and identify patients with increased risk. 
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